Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of NOXA mRNA was rapid, with a half-life of ~ 2 h, consistent with other published data showing a highly unstable mRNA36.”
From Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Despite the difficulties, successfully discovered small molecules that inhibit several PPIs have been reported [3,4].”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“It is known that ABT-263 causes reversible, dose-dependent, mechanism-based thrombocytopenia because of Bcl-xL inhibition in platelets [132] and it is expected that more specific inhibitors will be less toxic.”
BackgroundIdeker, T., & Sharan, R. (2008) · Genome Research · doi:10.1101/gr.071852.107 · Cited by 817
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603 · cited 1×
“Phase I studies in patients with SCLC and other solid tumors [115], as well as in lymphoid malignancies, showed that navitoclax is safe and well tolerated, with dose-dependent, reversible thrombocytopenia as the major adverse effect.”
BackgroundThe MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418 · cited 3×
“SAHBs are generated using a ring-closing metathesis reaction to construct an all hydrocarbon macrocyclic crosslink, thereby stabilizing peptide a-helices and significantly increasing the helicity and potency of a-helical peptides by transforming unfolded Bid, Bad and Bim BH3 peptides into proteaseresistant and cell-pe…”
Background
Research works printed but not linked: 87
- 10.1021/jm010468s · DOI · Paper page
- Cummings CG, 2010, Curr Opin Chem Biol, 14, 341, 10.1016/j.cbpa.2010.04.001 · DOI · Paper page
- 10.1038/sj.onc.1210220 · DOI · Paper page
- 10.1038/nrd2658 · DOI · Paper page
- 10.1038/cdd.2008.137 · DOI · Paper page
- 10.1038/nrm2308 · DOI · Paper page
- 10.1017/S096183680000331X · DOI · Paper page
- 10.1200/JCO.2005.02.4364 · DOI · Paper page
- Wang JL, 2000, Cancer Res, 60, 1498
- 10.1016/j.molcel.2006.08.020 · DOI · Paper page
- Kutzki O, 2002, J Am Chem Soc, 124, 11838, 10.1021/ja026861k · DOI · Paper page
- Davis JM, 2005, Org Lett, 7, 5405, 10.1021/ol0521228 · DOI
- Yin H, 2004, Bioorg Med Chem Lett, 14, 1375, 10.1016/j.bmcl.2003.09.096 · DOI
- 10.1038/35055085 · DOI · Paper page
- 10.1038/nature03579 · DOI · Paper page
- Petros AM, 2010, Bioorg Med Chem Lett, 20, 6587, 10.1016/j.bmcl.2010.09.033 · DOI
- 10.1021/jm0507532 · DOI · Paper page
- 10.1073/pnas.97.13.7124 · DOI · Paper page
- 10.1021/jm010016f · DOI · Paper page
- 10.1021/jm061152t · DOI · Paper page
- 10.1021/jm060460o · DOI · Paper page
- Wei J, 2010, J Med Chem, 53, 8000, 10.1021/jm100746q · DOI
- 10.1038/35055095 · DOI · Paper page
- Coutinho EM, 2000, Contraception, 61, 61, 10.1016/S0010-7824(99)00117-1 · doi:10.1016/s0010-7824(99)00117-1
- 10.1021/jm030190z · DOI · Paper page
- 10.4161/cbt.4.2.1441 · DOI · Paper page
- 10.1016/S0006-2952(03)00248-X · DOI · Paper page
- Oliver CL, 2005, Mol Cancer Ther, 4, 23, 10.1186/1476-4598-4-23 · doi:10.1186/1476-4598-4-23
- 10.1186/1476-4598-4-13 · DOI
- Atmaca H, 2009, Eur Cytokine Netw, 20, 121, 10.1684/ecn.2009.0159 · doi:10.1684/ecn.2009.0159
- 10.1158/1535-7163.MCT-08-0333 · DOI · Paper page
- 10.1593/neo.05691 · DOI
- Oliver CL, 2004, Clin Cancer Res, 10, 7757, 10.1158/1078-0432.CCR-04-0551 · DOI
- 10.1158/1535-7163.MCT-05-0081 · DOI · Paper page
- Zaidi R, 1992, Biochem Int, 28, 1135
- 10.1182/blood-2007-12-126946 · DOI
- Pang X, 2011, Mol Cancer Ther, 10, 795, 10.1158/1535-7163.MCT-10-0936 · DOI
- 10.4161/auto.6.8.13549 · doi:10.4161/auto.6.8.13549
- 10.1097/JTO.0b013e3181e8f4dc · DOI
- 10.1158/1078-0432.CCR-08-2985 · DOI · Paper page
- 10.4161/cbt.7.9.6430 · DOI
- 10.1002/ijc.23752 · doi:10.1002/ijc.23752
- Mi JX, 2008, Acta Pharmacol Sin, 29, 1467, 10.1111/j.1745-7254.2008.00901.x · doi:10.1111/j.1745-7254.2008.00901.x
- Banerjee S, 2010, Pancreas, 39, 323, 10.1097/MPA.0b013e3181bb95e7 · DOI
- 10.1182/blood-2007-09-113647 · DOI
- Coward L, 2006, J Pharm Biomed Anal, 42, 581, 10.1016/j.jpba.2006.05.020 · doi:10.1016/j.jpba.2006.05.020
- Wei J, 2009, Mol Cancer Ther, 8, 904, 10.1158/1535-7163.MCT-08-1050 · DOI
- Wei J, 2009, J Med Chem, 52, 4511, 10.1021/jm900472s · DOI
- 10.1021/jm1001265 · DOI
- 10.1073/pnas.1100769108 · DOI · Paper page
- Azab B, 2011, J Cell Physiol
- 10.1158/1078-0432.CCR-06-1574 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-3691 · DOI
- Ashimori N, 2009, Mol Cancer Ther, 8, 893, 10.1158/1535-7163.MCT-08-1078 · DOI
- 10.1002/ijc.23610 · DOI
- 10.1158/1078-0432.CCR-06-1574 · DOI · Paper page
- 10.1073/pnas.0709443104 · DOI · Paper page
- 10.1038/sj.cdd.4401937 · DOI · Paper page
- 10.1182/blood-2006-07-034173 · DOI · Paper page
- 10.1007/s00280007-0499-3 · doi:10.1007/s00280007-0499-3
- 10.1182/blood-2006-10-047951 · DOI · Paper page
- 10.1158/1535-7163.MCT08-0285 · doi:10.1158/1535-7163.mct08-0285
- 10.1158/10780432.CCR-08-1575 · doi:10.1158/10780432.ccr-08-1575
- Witters LM, 2007, Oncol Rep, 17, 465
- 10.1172/JCI39987 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-1919 · DOI · Paper page
- 10.1182/blood-2008-02-137943 · DOI · Paper page
- 10.1007/s00280010-1265-5 · doi:10.1007/s00280010-1265-5
- 10.1182/blood-2007-06-098012 · DOI · Paper page
- 10.1371/journal.pone.0009924 · DOI
- 10.1038/sj.leu.2404719 · DOI · Paper page
- 10.1038/sj.onc.1210028 · DOI · Paper page
- 10.1016/j.ccr.2006.10.006 · DOI · Paper page
- 10.1172/JCI28281 · DOI · Paper page
- Vogler M, 2008, Cell Death Differ, 15, 820, 10.1038/cdd.2008.25 · DOI
- 10.1182/blood-2007-03-080325 · DOI · Paper page
- High LM, 2010, Mol Pharmacol, 77, 483, 10.1124/mol.109.060780 · DOI
- 10.1158/1078-0432.CCR-07-4622 · DOI · Paper page
- 10.1016/j.ccr.2006.08.027 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-3964 · DOI · Paper page
- 10.1073/pnas.0701297104 · DOI · Paper page
- 10.1038/cdd.2009.48 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-2508 · DOI · Paper page
- 10.1038/onc.2008.259 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-1418 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-1526 · DOI · Paper page
- 10.1016/j.ccr.2007.07.001 · DOI · Paper page
Cited by
A review on anticancer potential of bioactive heterocycle quinoline
Afzal, O., Kumar, S., Haider, M. R., Ali, M. R., Kumar, R., Jaggi, M., & Bawa, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.044 · Cited by 798
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Metadata
- Authors
- Bajwa, N., Liao, C., & Nikolovska-Coleska, Z.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2011-12-23
- Volume
- 22
- Issue
- 1
- Pages
- 37-55
- ISSN
- 1354-3776
- 1744-7674
- Cited by
- 91
- References
- 13
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. https://app.cochat.ai/papers/10.1517/13543776.2012.644274
- The paper
- Bajwa, N., Liao, C., & Nikolovska-Coleska, Z. (2012). Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2012.644274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.